EAU Guidelines on Non???Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013, European Urology, vol.64, issue.4, pp.639-53, 2013. ,
DOI : 10.1016/j.eururo.2013.06.003
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends, European Urology, vol.71, issue.1, pp.96-108, 2017. ,
DOI : 10.1016/j.eururo.2016.06.010
The present and future burden of urinary bladder cancer in the world, World Journal of Urology, vol.102, issue.2, pp.289-93, 2009. ,
DOI : 10.1007/s00345-009-0383-3
Surgical Advances in Bladder Cancer, Urologic Clinics of North America, vol.42, issue.2, pp.235-52, 2015. ,
DOI : 10.1016/j.ucl.2015.01.005
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.33, issue.2, pp.40-48, 2014. ,
DOI : 10.1086/321805
Recurrence and Progression of Disease in Non???Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy, European Urology, vol.56, issue.3, pp.430-472, 2009. ,
DOI : 10.1016/j.eururo.2009.06.028
Recommandations en onco-urologie 2016-2018 du CCAFU : Tumeurs de la vessie, Progr??s en Urologie, vol.27, issue.1, pp.67-91, 2016. ,
DOI : 10.1016/S1166-7087(16)30704-7
Chemotherapy for Metastatic or Unresectable Bladder Cancer, Seminars in Oncology, vol.34, issue.2, pp.135-179, 2007. ,
DOI : 10.1053/j.seminoncol.2006.12.008
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract, Journal of Clinical Oncology, vol.27, issue.27, pp.4454-61, 2009. ,
DOI : 10.1200/JCO.2008.20.5534
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, vol.45, issue.7528, pp.558-62, 2014. ,
DOI : 10.1016/j.ejca.2008.10.026
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, The Lancet, vol.387, issue.10031, pp.1909-1929, 2016. ,
DOI : 10.1016/S0140-6736(16)00561-4
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, New England Journal of Medicine, vol.376, issue.11, pp.1015-1041, 2017. ,
DOI : 10.1056/NEJMoa1613683
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, The Lancet Oncology, vol.18, issue.3, pp.312-334, 2017. ,
DOI : 10.1016/S1470-2045(17)30065-7
Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC), J Clin Oncol, vol.35, p.4525, 2017. ,
Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial., Journal of Clinical Oncology, vol.35, issue.6_suppl, p.330, 2017. ,
DOI : 10.1200/JCO.2017.35.6_suppl.330
Targeting the genetic alterations of the PI3K???AKT???mTOR pathway: Its potential use in the treatment of bladder cancers, Pharmacology & Therapeutics, vol.145, pp.1-18, 2015. ,
DOI : 10.1016/j.pharmthera.2014.06.004
Rapamycin Inhibits In Vitro Growth and Release of Angiogenetic Factors in Human Bladder Cancer, Urology, vol.73, issue.3, pp.665-674, 2009. ,
DOI : 10.1016/j.urology.2008.09.070
mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma, Oncol Rep, vol.25, pp.763-771, 2011. ,
Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer, Cancer Biology & Therapy, vol.8, issue.24, pp.2339-2386, 2009. ,
DOI : 10.4161/cbt.8.24.9987
In vivo and in vitro effects of RAD001 on bladder cancer, vivo and in vitro effects of RAD001 on bladder cancer, pp.1212-1233, 2013. ,
DOI : 10.1016/j.urolonc.2011.11.002
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial, The Lancet, vol.381, issue.9861, pp.125-157, 2013. ,
DOI : 10.1016/S0140-6736(12)61134-9
Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.32, issue.8, pp.760-767, 2014. ,
DOI : 10.1200/JCO.2013.50.3961
Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial, Journal of Clinical Oncology, vol.32, issue.8, pp.752-761, 2014. ,
DOI : 10.1200/JCO.2013.50.5305
Everolimus in Postmenopausal Hormone-Receptor???Positive Advanced Breast Cancer, New England Journal of Medicine, vol.366, issue.6, pp.520-529, 2012. ,
DOI : 10.1056/NEJMoa1109653
Everolimus for Advanced Pancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.364, issue.6, pp.514-537, 2011. ,
DOI : 10.1056/NEJMoa1009290
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers, Annals of Oncology, vol.26, issue.10, pp.2663-70, 2012. ,
DOI : 10.1038/sj.onc.1209990
Phase II study of everolimus in metastatic urothelial cancer, BJU International, vol.27, issue.4, pp.462-70, 2013. ,
DOI : 10.1200/JCO.2009.22.9054
Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer, Journal of Clinical Oncology, vol.31, issue.25, pp.3133-3173, 2013. ,
DOI : 10.1200/JCO.2012.46.5740
A phase II trial of temsirolimus in second-line metastatic urothelial cancer, Medical Oncology, vol.28, issue.4, pp.2870-2876, 2012. ,
DOI : 10.1200/JCO.2011.37.7002
Safety and efficacy of temsirolimus as second-line treatment for patients with recurrent bladder cancer., Journal of Clinical Oncology, vol.33, issue.7_suppl, p.304, 2015. ,
DOI : 10.1200/jco.2015.33.7_suppl.304
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 2009. ,
DOI : 10.1016/j.ejca.2008.10.026
Optimal two-stage designs for phase II clinical trials, Controlled Clinical Trials, vol.10, issue.1, pp.1-10, 1989. ,
DOI : 10.1016/0197-2456(89)90015-9
URL : http://linus.nci.nih.gov/techreport/Optimal2-StageDesigns.pdf
Sample size tables for clinical studies, 2009. ,
DOI : 10.1002/9781444300710
Role in bladder cancer prognosis and targeted therapeutics, PLoS One, vol.10, p.141253, 2015. ,
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN), Annals of Oncology, vol.15, issue.9747, pp.1517-1539, 2017. ,
DOI : 10.1186/s12885-015-1434-3
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma, BJU International, vol.73, issue.3, pp.408-423, 2016. ,
DOI : 10.1007/s10637-015-0218-6
Genome Sequencing Identifies a Basis for Everolimus Sensitivity, Science, vol.68, issue.22, p.221, 2012. ,
DOI : 10.1158/0008-5472.CAN-08-2223
Comparing RECIST with EORTC criteria in metastatic bladder cancer, Journal of Cancer Research and Clinical Oncology, vol.43, issue.9, pp.187-94, 2016. ,
DOI : 10.1093/jjco/hyt096
Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions, Cancers, vol.7, issue.12, p.15, 2017. ,
DOI : 10.1002/cncr.23848
Combining immunotherapy and targeted therapies in cancer treatment, Nature Reviews Cancer, vol.12, issue.4, pp.237-51, 2012. ,
DOI : 10.1038/nrc3239
Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition, Urologic Oncology: Seminars and Original Investigations, vol.35, issue.10, pp.593-602, 2017. ,
DOI : 10.1016/j.urolonc.2017.03.025